European Agency Supports Marketing of Abrocitinib for AD European Agency Supports Marketing of Abrocitinib for AD

The oral JAK inhibitor is under review at the FDA for the same indication.Medscape Medical News
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Dermatology News Source Type: news
More News: Dermatology | Marketing | Skin